نتائج البحث - "Karen Afenjar"

1

دورية أكاديمية

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy endocrine therapy alone in patients with HR+/HER2− early breast cancer

المصدر: Therapeutic Advances in Medical Oncology, Vol 15 (2023)

مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1758-8359Test

الوصول الحر: https://doaj.org/article/73d02bee3f9e4dc6a76bef48c3ed8ce0Test

View record in DOAJ

النص الكامل

2

Supplementary Data. from HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dcefbe9e663b9232264cc987f8bc9cbTest
https://doi.org/10.1158/1535-7163.22508224.v1Test

3

Abstract PD12-06: Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial

المصدر: Cancer Research. 81:PD12-06

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, Carboplatin, chemistry.chemical_compound, chemistry, Docetaxel, Trastuzumab, Internal medicine, medicine, Amenorrhea, Pertuzumab, medicine.symptom, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::88d84f71b93e4579fa057e9a3897306fTest
https://doi.org/10.1158/1538-7445.sabcs20-pd12-06Test

4

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 37, iss 25
Journal of Clinical Oncology

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, Receptor, ErbB-2, medicine.medical_treatment, Docetaxel, Kaplan-Meier Estimate, Ado-Trastuzumab Emtansine, Carboplatin, chemistry.chemical_compound, ErbB-2, 0302 clinical medicine, Trastuzumab, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humanized, Adjuvant, Neoadjuvant therapy, Middle Aged, Neoadjuvant Therapy, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Pertuzumab, RAPID COMMUNICATION, Receptor, medicine.drug, Adult, medicine.medical_specialty, Clinical Sciences, Oncology and Carcinogenesis, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Antibodies, Disease-Free Survival, 03 medical and health sciences, Breast cancer, Internal medicine, Breast Cancer, Chemotherapy, Humans, Oncology & Carcinogenesis, Aged, business.industry, medicine.disease, 030104 developmental biology, chemistry, Trastuzumab emtansine, business

وصف الملف: Print-Electronic; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::108221c07fe98c1622828a09784f0ec6Test
https://doi.org/10.1200/jco.19.00882Test

5

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

المصدر: The Lancet Oncology. 19:115-126

مصطلحات موضوعية: 0301 basic medicine, Oncology, Time Factors, Receptor, ErbB-2, medicine.medical_treatment, Docetaxel, Ado-Trastuzumab Emtansine, Carboplatin, chemistry.chemical_compound, 0302 clinical medicine, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, skin and connective tissue diseases, Neoadjuvant therapy, education.field_of_study, Middle Aged, Neoadjuvant Therapy, Europe, Treatment Outcome, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Taxoids, Pertuzumab, medicine.drug, Adult, Canada, medicine.medical_specialty, Asia, Population, Breast Neoplasms, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Internal medicine, Biomarkers, Tumor, medicine, Humans, Maytansine, education, neoplasms, Neoplasm Staging, Chemotherapy, business.industry, United States, 030104 developmental biology, chemistry, Trastuzumab emtansine, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6c47a3b25c47a9cd4777e62d2a8e8eaTest
https://doi.org/10.1016/s1470-2045Test(17)30716-7

6

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial

المصدر: Journal of Clinical Oncology. 34:443-451

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::5c62b00f00b6dbed894c039b7695a3b2Test
https://doi.org/10.1200/jco.2015.62.6598Test

7

Results from TRIO030, a pre-surgical tissue-acquisition study to evaluate molecular alterations in human breast cancer tissue following short-term exposure to the androgen receptor antagonist darolutamide

المؤلفون: Michael F. Press, Angela Santiago, Ivonne Villalobos, E. Von Euw, Hsiao-Wang Chen, DJ Slamon, Karen Afenjar, Rodrigo Fresco, H. Fung, Roberta Guzman, S. Carrez, M. Burton, Wolfgang Eiermann, P. Millan

المصدر: Annals of Oncology. 30:v53

مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Hematology, medicine.disease, Androgen receptor, Cytokeratin, Darolutamide, Breast cancer, Internal medicine, Gene expression, medicine, Immunohistochemistry, business, Neoadjuvant therapy, Triple-negative breast cancer

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::50fc0a0106b3039f0b0b71fe52d6ec5cTest
https://doi.org/10.1093/annonc/mdz239.076Test

8

HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib

المصدر: Molecular cancer therapeutics. 16(1)

مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Esophageal Neoplasms, Receptor, ErbB-2, medicine.medical_treatment, Concordance, Population, Adenocarcinoma, Lapatinib, HercepTest, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Stomach Neoplasms, Internal medicine, medicine, Humans, skin and connective tissue diseases, education, neoplasms, Protein Kinase Inhibitors, In Situ Hybridization, Fluorescence, Aged, Aged, 80 and over, Chemotherapy, education.field_of_study, business.industry, Cancer, Esophageal cancer, Middle Aged, medicine.disease, Immunohistochemistry, Clinical trial, 030104 developmental biology, Treatment Outcome, 030220 oncology & carcinogenesis, Quinazolines, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b780760ea58ba4b3d48030a7403b58eTest
https://pubmed.ncbi.nlm.nih.gov/27811012Test

9

Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer

المصدر: JAMA Oncology. 3:767

مصطلحات موضوعية: Male, 0301 basic medicine, Cancer Research, medicine.medical_specialty, Esophageal Neoplasms, Organoplatinum Compounds, medicine.drug_class, Colorectal cancer, Proton-pump inhibitor, Lapatinib, Gastroenterology, law.invention, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Stomach Neoplasms, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Drug Interactions, Original Investigation, business.industry, Hazard ratio, Correction, Proton Pump Inhibitors, Middle Aged, medicine.disease, Oxaliplatin, Surgery, Treatment Outcome, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Quinazolines, Female, Erlotinib, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c8e55284cdbce6fe160b47216cc6e70Test
https://doi.org/10.1001/jamaoncol.2016.3358Test

10

Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE)

المؤلفون: Chiun-Sheng Huang, Jin Xu, Joseph A. Sparano, Hans Wildiers, Nadia Harbeck, Rodrigo Fresco, Daniil Stroyakovskiy, Karen Afenjar, Vicente Valero, William Fraser Symmans, Sara A. Hurvitz, Hans-Joachim Helms, Miguel Martin, Yvonne G. Lin, Alastair M. Thompson, Dennis J. Slamon, Kyung Hae Jung

المصدر: Journal of Clinical Oncology. 34:500-500

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::c5304f3cd3b92b79895841b142edb06dTest
https://doi.org/10.1200/jco.2016.34.15_suppl.500Test

تنقيح النتائج